The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
Raffaella Soldi(Banner Health), Sunil Sharma(Translational Genomics Research Institute), Alexis Weston(Translational Genomics Research Institute), Bernard E. Weissman(University of North Carolina at Chapel Hill), Sherin Daniel Ampanattu(Translational Genomics Research Institute), Mohan R. Kaadige(Translational Genomics Research Institute), Shreyesi Srivastava(Clinical Research Institute), Kevin Drenner(Translational Genomics Research Institute), Jeffrey M. Trent(Translational Genomics Research Institute), Tithi Ghosh(Translational Genomics Research Institute), Trason Thode(Translational Genomics Research Institute), Rhonda Lewis(Translational Genomics Research Institute), Ryan Rodriguez del Villar(Translational Genomics Research Institute), Jessica D. Lang(Translational Genomics Research Institute), Hariprasad Vankayalapati(University of Utah), William P.D. Hendricks(Translational Genomics Research Institute)
Cited by 82
Related Papers
Common sequence variants on 20q11.22 confer melanoma susceptibility
|Nature Genetics|2008|226
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3
|Nature Genetics|2011|157